NGM831 + pembrolizumab

NGM831 + pembrolizumab is an investigational combination therapy being evaluated for the treatment of advanced or metastatic solid tumors, including colorectal cancer, melanoma, mesothelioma, and others. NGM831 is a monoclonal antibody that acts as an antagonist of Immunoglobulin-like transcript 3 (ILT3, also known as LILRB4), a myeloid immune checkpoint thought to suppress anti-tumor immunity. Pembrolizumab is a well-established monoclonal antibody targeting the Programmed cell death protein 1 (PD-1) receptor on T cells, blocking its interaction with PD-L1 and PD-L2 to enhance immune responses against tumors. The combination aims to improve anti-tumor activity by simultaneously inhibiting two distinct immunosuppressive pathways in the tumor microenvironment. The developer of NGM831 is NGM Biopharmaceuticals; pembrolizumab was developed by Merck & Co., marketed under the brand name Keytruda[2][5][8].

Other names

anti-LILRB4 monoclonal antibody (for NGM831)